1GERN Stock Overview

A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. More details

1GERN fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 89.1% below our estimate of its fair value

Earnings are forecast to grow 65.3% per year

Risk Analysis

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Geron Corporation Competitors

Philogen

BIT:PHIL

€878.3m

Ulisse Biomed

BIT:UBM

€18.3m

Iovance Biotherapeutics

NasdaqGM:IOVA

US$1.1b

Day One Biopharmaceuticals

NasdaqGS:DAWN

US$758.1m

Price History & Performance

Summary of share price highs, lows and changes for Geron
Historical stock prices
Current Share Price	US$1.25
52 Week High	US$0
52 Week Low	US$0
Beta	0.76
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	1GERN	IT Biotechs	IT Market
7D	0%	2.3%	2.1%
1Y	n/a	4.3%	12.2%

Return vs Industry: Insufficient data to determine how 1GERN performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1GERN performed against the Italian Market.

Price Volatility

Is 1GERN's price volatile compared to industry and market?
1GERN volatility
1GERN Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.2%
Market Average Movement	5.3%
10% most volatile stocks in IT Market	8.7%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1GERN's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1GERN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1990	229	Dawn Bir	www.geron.com

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation Fundamentals Summary

How do Geron's earnings and revenue compare to its market cap?
1GERN fundamental statistics
Market cap	€795.07m
Earnings (TTM)	-€153.47m
Revenue (TTM)	€67.69m

10.9x

P/S Ratio

-4.8x

P/E Ratio

Is 1GERN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1GERN income statement (TTM)
Revenue	US$76.99m
Cost of Revenue	US$104.99m
Gross Profit	-US$28.00m
Other Expenses	US$146.57m
Earnings	-US$174.57m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 07, 2025

Earnings per share (EPS)	-0.27
Gross Margin	-36.37%
Net Profit Margin	-226.73%
Debt/Equity Ratio	42.3%

How did 1GERN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/06 15:04
End of Day Share Price	2025/05/06 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Geron Corporation is covered by 27 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Carter Gould	Barclays
Peter Lawson	Barclays
George Zavoico	B. Riley Securities, Inc.